Supported by

TAVI (Transcatheter aortic valve implantation)

Find all the latest content on TAVI published on this website.

TAVI, now an established, valid treatment for patients presenting with symptomatic severe aortic stenosis, has proven to be superior to medical treatment for inoperable patients whilst being a valid alternative to surgery in select, high-risk patients. This topic covers the newest devices and emerging data in TAVI as well as information on tools, devices and techniques such as vascular access; the role of adjunctive pharmacotherapy; imaging techniques such as echocardiography, understanding bleeding risks or patient selection. Use the filters below to access PCRonline resources.

Anatomy of the aortic valvar complex

View a detailed and comprehensive description of the anatomy of the aortic valvar complex as it pertains to TAVI.

View illustrated aortic valvar complex

Filtered By
TAVI

1602 results

Challenges and solutions in an expanding TAVI world

20 May 2025 – From EuroPCR 2025

This EuroPCR 2025 session addresses key challenges and emerging solutions in today’s rapidly evolving TAVI landscape. It presents the latest evidence on valve replacement in low-risk patients with aortic stenosis, alongside strategies for navigating the complexities of lifetime management in TAVI candidates. The programme features a...

Challenges and solutions in an expanding TAVI world

PCR's Got Talent Round 1 - Session 1

20 May 2025 – From EuroPCR 2025

Experience a diverse range of cutting-edge interventional cardiology topics in PCR's Got Talent Round 1. This session features presentations on PFO closure outcomes, plaque morphology, vascular injury treatments, microvascular disease assessment, TAVI-related coronary obstruction prediction, novel FFR surrogates, and more.

PCR's Got Talent Round 1 - Session 1

How to manage coronary artery disease in TAVI candidates?

20 May 2025 – From EuroPCR 2025

Understand the comprehensive management of coronary artery disease (CAD) in patients undergoing transcatheter aortic valve implantation (TAVI). This session reviews evidence-based evaluation, decision-making, and treatment strategies for significant coronary lesions, including severe left main and multivessel disease, illustrated through detailed case studies.

How to manage coronary artery disease in TAVI candidates?

TAVI in patients with a small annulus

20 May 2025 – From EuroPCR 2025

Address the unique challenges of transcatheter aortic valve implantation (TAVI) in patients with small aortic annuli. This session discusses comparative outcomes of balloon-expandable versus self-expandable valves, size prediction methodologies, and management of paravalvular regurgitation in low-flow, low-gradient aortic stenosis cases.

TAVI in patients with a small annulus

Complex PCI in a TAVI patient - LIVE case

20 May 2025 – From EuroPCR 2025

An 84-year-old patient with a history of ischemic stroke in 2017, hypertension, diabetes, dyslipidemia, and a preserved LV function (63 %) presented with a severe symptomatic aortic stenosis. The coronary angiography revealed a severe and calcified stenosis of the distal left main.
Operators implanted an Edwards Sapien...

Complex PCI in a TAVI patient - LIVE case

PCR's Got Talent Round 1 - Session 2

20 May 2025 – From EuroPCR 2025

Join the dynamic PCR's Got Talent Round 1 - Session 2 featuring cutting-edge research and innovations in interventional cardiology. Highlights include complex CTO PCI strategies, valve comparisons in TAVI for small annuli, PFO closure outcomes, long-term PCI durability, CT-guided robotic PCI, pacemaker prediction post-TAVI, and much...

PCR's Got Talent Round 1 - Session 2

TAVI in bicuspid aortic valve disease - LIVE Case

20 May 2025 – From EuroPCR 2025

A 79-year-old male patient with atrial fibrillation and RBBB on ECG presented with symptomatic severe bicuspid aortic stenosis. LV function was preserved, and coronary artery disease was noted in LAD and first diagonal. A 26 mm Sapien Ultra Resilia valve was implanted via dual femoral access,...

TAVI in bicuspid aortic valve disease - LIVE Case

TAVI - Procedural complications

20 May 2025 – From EuroPCR 2025

Review procedural complications encountered during TAVI, including rare adverse events, management of balloon rupture, annulus rupture with tamponade, and unexpected intraoperative challenges. Gain insights into innovative rescue techniques and decision-making under critical conditions.

TAVI - Procedural complications

Prevention of coronary obstruction during TAV-in-TAV

20 May 2025 – From EuroPCR 2025

Examine advanced techniques to prevent coronary obstruction during transcatheter aortic valve-in-valve (TAV-in-TAV) procedures. This session presents complex case strategies including the debated chimney technique and the UNICORN procedure designed for high coronary obstruction risk during redo TAVI interventions.

Prevention of coronary obstruction during TAV-in-TAV

Degeneration of TAVI valves: a new target for innovations

19 May 2025 – From EuroPCR 2025

Discover the latest innovations targeting degeneration of TAVI valves, including expert presentations and cutting-edge technologies like The Splitter, an enabler for transcatheter aortic valve-in-valve implantation.

Degeneration of TAVI valves: a new target for innovations

The Jon DeHaan Foundation Award competition

19 May 2025 – From EuroPCR 2025

Witness innovation in action at the Jon DeHaan Foundation Award competition featuring groundbreaking technologies like synchronized diaphragmatic stimulation for heart failure and novel devices for aortic bioprosthesis and interatrial shunting.

The Jon DeHaan Foundation Award competition

Learnings from LANDMARK and Compare-TAVI at 3 years

22 May 2025 – From EuroPCR 2025

At EuroPCR 2025, Andreas Baumbach, Christian Juhl Terkelsen and Didier Tchetche reviewed the latest findings from the LANDMARK and Compare-TAVI 1 trials—both focused on the performance of the Myval balloon-expandable valve.

LANDMARK compared Myval and Myval Octacor to leading self-expanding valves in a randomised controlled trial. At...

Learnings from LANDMARK and Compare-TAVI at 3 years

How to manage the challenges of TAVI in bicuspid disease?

22 May 2025 – From EuroPCR 2025

How should TAVI be adapted to the unique challenges of bicuspid aortic valve disease? In this EuroPCR 2025 discussion, Chiara De Biase, Kentaro Hayashida, and Didier Tchetche explore the key anatomical and procedural considerations for tailoring treatment. From selecting which bicuspid anatomies are suitable for TAVI...

How to manage the challenges of TAVI in bicuspid disease?

Redo TAVI: how to treat different TAVI platforms when they fail?

22 May 2025 – From EuroPCR 2025

In this discussion, Tanja Rudolph, Dan Blackman, and Radoslaw Parma take a deep dive into the current understanding of redo TAVR.

Together, they address the main challenges faced in repeat procedures - chiefly, the risk of coronary obstruction and the importance of preserving coronary access, alongside strategies...

Redo TAVI: how to treat different TAVI platforms when they fail?

Learnings from Evolut Low Risk 5-year and SMART 2-year trials : from evidence to practice

21 May 2025 – From EuroPCR 2025

At EuroPCR 2025, Angela McInerney, Didier Tchétché, and Ole De Backer discuss key results from the SMART and Evolut Low Risk trials. The SMART trial compared balloon-expandable and self-expanding valves in small annulus patients, showing better hemodynamics with the Evolut platform at 2 years. The Evolut...

Learnings from Evolut Low Risk 5-year and SMART 2-year trials : from evidence to practice

How will EARLY-TAVI and NOTION-3 impact TAVI practice?

21 May 2025 – From EuroPCR 2025

When is the right time to perform TAVI—and how should coexisting coronary artery disease be managed? In this interview, Liesbeth Rosseel, Davide Capodanno, and Michael Joner tackle these two timely questions. They share key takeaways from the EARLY-TAVI trial, which demonstrated reduced rehospitalisation with early intervention...

How will EARLY-TAVI and NOTION-3 impact TAVI practice?

Major LBTs from EuroPCR 2025 - Meta-Analysis of individual patient data from the PROTECTED TAVR and BHF PROTECT-TAVI studies

22 May 2025 – From EuroPCR 2025

Stroke remains one of the most feared complications of TAVI—for both patients and physicians. In this EuroPCR 2025 video interview, Bernard Prendergast and Rajesh Kharbanda examine the role of cerebral protection during TAVI procedures, in light of two randomised trials: PROTECTED TAVR and BHF PROTECT-TAVI. While...

Meta-Analysis from the PROTECTED TAVR and BHF PROTECT-TAVI studies

Hotline - ACURATE neo2 under-expansion in the ACURATE IDE study: a post-hoc analysis

21 May 2025 – From EuroPCR 2025

Howard Herrmann and Raj Makkar discuss a sub-study of the ACURATE IDE trial, which examined valve under-expansion detected by fluoroscopy. Among 1,500 patients with aortic stenosis, 22 % of ACURATE neo2 valves showed under-expansion, often linked to heavy valve calcification.

Patients with under-expanded valves faced higher risks...

ACURATE neo2 under-expansion in the ACURATE IDE study: a post-hoc analysis

What are the emerging indications for TAVI in 2025?

22 May 2025 – From EuroPCR 2025

Tiffany Patterson, Nicolas Van Mieghem, and Philippe Généreux discuss emerging indications for TAVI in 2025. They review recent evidence on asymptomatic severe aortic stenosis, highlighting four randomised trials—RECOVERY, AVATAR, ONLY TAVR, and EVoLVeD—that show TAVI or surgical AVR reduces hospitalisations for heart failure and trends toward...

What are the emerging indications for TAVI in 2025?

Hotline from EuroPCR 2025 - Five-year outcomes from the Evolut low risk TAVR bicuspid study

21 May 2025 – From EuroPCR 2025

Simon Redwood and John Forrest exchange insights on the Evolut Low Risk Bicuspid Study, which explores transcatheter aortic valve replacement (TAVR) in younger, low-risk patients with bicuspid aortic valves—an anatomy often excluded from earlier trials.

They review the trial design, patient characteristics, and results, comparing outcomes with...

Five-year outcomes from the Evolut low risk TAVR bicuspid study